Cargando…
Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial
BACKGROUND: Solriamfetol is approved (US and EU) for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea. OBJECTIVES: Evaluate solriamfetol safety/efficacy for EDS in Parkinson's disease (PD). METHODS: Phase 2, double‐blind, 4‐week, crossover trial: adults with PD and E...
Autores principales: | Videnovic, Aleksandar, Amara, Amy W., Comella, Cynthia, Schweitzer, Paula K., Emsellem, Helene, Liu, Kris, Sterkel, Amanda L., Gottwald, Mildred D., Steinerman, Joshua R., Jochelson, Philip, Zomorodi, Katie, Hauser, Robert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596433/ https://www.ncbi.nlm.nih.gov/pubmed/34191352 http://dx.doi.org/10.1002/mds.28702 |
Ejemplares similares
-
A randomized study of solriamfetol for excessive sleepiness in narcolepsy
por: Thorpy, Michael J., et al.
Publicado: (2019) -
Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment
por: Schweitzer, Paula K., et al.
Publicado: (2021) -
Effects of solriamfetol on on‐the‐road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea
por: Vinckenbosch, Frederick, et al.
Publicado: (2022) -
Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives
por: Abad, Vivien C
Publicado: (2021) -
Increased Serum Prolactin and Excessive Daytime Sleepiness: An Attempt of Proof-of-Concept Study
por: Mogavero, Maria P., et al.
Publicado: (2021)